Borealis Biosciences

About Borealis Biosciences

Borealis Biosciences develops RNA therapeutics specifically targeting kidney diseases, utilizing advanced methods for targeted delivery to renal cells. The company addresses the lack of effective treatments for prevalent chronic kidney conditions, aiming to improve patient outcomes and reduce the incidence of kidney failure.

```xml <problem> Chronic kidney diseases affect a significant portion of the global population, and many prevalent forms lack effective treatments. This can lead to kidney failure, requiring dialysis or transplantation, and significantly impacting patients' lives. Validated causal targets for these diseases have not been amenable to traditional small molecule or biologic modalities. </problem> <solution> Borealis Biosciences is developing RNA therapeutics specifically designed to address kidney diseases with high unmet need. The company focuses on directing RNA to kidney cells, leveraging scientific and translational breakthroughs in RNA medicines. Borealis' approach aims to improve patient outcomes and reduce the incidence of kidney failure by targeting previously inaccessible disease mechanisms. Their experienced team utilizes expertise in kidney disease, targeted delivery of RNA therapeutics, and translational systems biology to develop these novel treatments. </solution> <features> - Targeted delivery of RNA therapeutics to kidney cells - Focus on kidney diseases with large unmet needs - Utilizes translational systems biology and data sciences - Development of RNA medicines to treat kidney diseases </features> <target_audience> The primary target audience includes patients suffering from chronic kidney diseases and the healthcare providers who treat them. </target_audience> ```

What does Borealis Biosciences do?

Borealis Biosciences develops RNA therapeutics specifically targeting kidney diseases, utilizing advanced methods for targeted delivery to renal cells. The company addresses the lack of effective treatments for prevalent chronic kidney conditions, aiming to improve patient outcomes and reduce the incidence of kidney failure.

Where is Borealis Biosciences located?

Borealis Biosciences is based in Vancouver, Canada.

When was Borealis Biosciences founded?

Borealis Biosciences was founded in 2024.

How much funding has Borealis Biosciences raised?

Borealis Biosciences has raised 30000000.

Who founded Borealis Biosciences?

Borealis Biosciences was founded by Christian Hordo.

  • Christian Hordo - President/CEO
Location
Vancouver, Canada
Founded
2024
Funding
30000000
Employees
27 employees
Major Investors
Westlake Village BioPartners
Looking for specific startups?
Try our free semantic startup search

Borealis Biosciences

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Borealis Biosciences develops RNA therapeutics specifically targeting kidney diseases, utilizing advanced methods for targeted delivery to renal cells. The company addresses the lack of effective treatments for prevalent chronic kidney conditions, aiming to improve patient outcomes and reduce the incidence of kidney failure.

borealisbio.com3K+
cb
Crunchbase
Founded 2024Vancouver, Canada

Funding

$

Estimated Funding

$30M+

Major Investors

Westlake Village BioPartners

Team (25+)

Christian Hordo

President/CEO

Company Description

Problem

Chronic kidney diseases affect a significant portion of the global population, and many prevalent forms lack effective treatments. This can lead to kidney failure, requiring dialysis or transplantation, and significantly impacting patients' lives. Validated causal targets for these diseases have not been amenable to traditional small molecule or biologic modalities.

Solution

Borealis Biosciences is developing RNA therapeutics specifically designed to address kidney diseases with high unmet need. The company focuses on directing RNA to kidney cells, leveraging scientific and translational breakthroughs in RNA medicines. Borealis' approach aims to improve patient outcomes and reduce the incidence of kidney failure by targeting previously inaccessible disease mechanisms. Their experienced team utilizes expertise in kidney disease, targeted delivery of RNA therapeutics, and translational systems biology to develop these novel treatments.

Features

Targeted delivery of RNA therapeutics to kidney cells

Focus on kidney diseases with large unmet needs

Utilizes translational systems biology and data sciences

Development of RNA medicines to treat kidney diseases

Target Audience

The primary target audience includes patients suffering from chronic kidney diseases and the healthcare providers who treat them.